title: Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
abstract: The Pneumococcal Surface Protein A (PspA) is a promising candidate for the composition of a protein vaccine against Streptococcus pneumoniae. We have previously shown that the whole cell Bordetella pertussis vaccine (wP) is a good adjuvant to PspA, inducing protective responses against pneumococcal infection in mice. In Brazil, wP is administered to children, formulated with diphtheria and tetanus toxoids (DTPw) and aluminum hydroxide (alum) as adjuvant. A single subcutaneous dose of PspA5-DTPlow (a formulation containing PspA from clade 5 and a new generation DTPw, containing low levels of B. pertussis LPS and Alum) induced high levels of systemic anti-PspA5 antibodies in mice and conferred protection against respiratory lethal challenges with two different pneumococcal strains. Here we evaluate the mucosal immune responses against PspA5 as well as the immune responses against the DTP antigens in mice vaccinated with PspA5-DTPlow. Subcutaneous immunization of mice with PspA5-DTPlow induced high levels of anti-PspA5 IgG in the airways but no IgA. In addition, no differences in the influx of cells to the respiratory mucosa, after the challenge, were observed in vaccinated mice, when compared with control mice. The levels of circulating anti-pertussis, -tetanus and -diphtheria antibodies were equivalent in mice vaccinated with DTPlow or PspA5-DTPlow. Antibodies induced by DTPlow or PspA5-DTPlow showed similar ability to neutralize the cytotoxic effects of the diphtheria toxin on Vero cells. Furthermore, combination with PspA5 did not affect protection against B. pertussis and tetanus toxin challenges in mice. Our results support the proposal for a combined PspA-DTP vaccine.
authors.affiliation: Centro de Biotecnologia, Instituto Butantan, São Paulo, SP, Brazil.
authors.forename: Fernanda A
authors.initials: FA
authors.lastname: Lima
authors.forename: Eliane N
authors.initials: EN
authors.lastname: Miyaji
authors.forename: Wagner
authors.initials: W
authors.lastname: Quintilio
authors.forename: Isaias
authors.initials: I
authors.lastname: Raw
authors.forename: Paulo L
authors.initials: PL
authors.lastname: Ho
authors.forename: Maria Leonor S
authors.initials: ML
authors.lastname: Oliveira
mesh_terms: D000534:Alum Compounds; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000097:blood / Q000276:immunology; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology*; D001886:Bordetella pertussis / Q000276:immunology; D002522:Chlorocebus aethiops; D004167:Diphtheria Toxin / Q000037:antagonists & inhibitors / Q000276:immunology; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood / Q000276:immunology; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D037342:Pertussis Toxin / Q000037:antagonists & inhibitors / Q000276:immunology; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D020545:Respiratory Mucosa / Q000276:immunology; D013296:Streptococcus pneumoniae / Q000276:immunology; D013744:Tetanus Toxin / Q000037:antagonists & inhibitors / Q000276:immunology; D014611:Vaccination; D014709:Vero Cells
chemical_list: D000534:Alum Compounds; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D004167:Diphtheria Toxin; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D022242:Pneumococcal Vaccines; D013744:Tetanus Toxin; C051592:pneumococcal surface protein A; C041524:aluminum sulfate; D037342:Pertussis Toxin